The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis
Open accessAbstract
The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, omalizumab has been associated with anaphylactic reactions in 0.09% to 0.2% of patients, with current recommendations to monitor patients for 30 minutes following administration.1742,1743”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The estimated rate of systemic reaction from a pollen-food allergy is 10% and the estimated rate of anaphylaxis is 1.7% to 10%.1742,1919,1920”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N., Bock, S. A., Branum, A., Brown, S., Camargo, C. A., Cydulka, R., Galli, S., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,170
Self-citationSymposium on the definition and management of anaphylaxis: summary report.
Sampson, H., Muñoz-Furlong, A., Bock, S., Schmitt, C., Bass, R., Chowdhury, B., Decker, W., Furlong, T., Galli, S., Golden, D., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 640
Self-citationThe Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience
Cheifetz, A. S., Smedley, M. V., Martin, S., Reiter, M., Leone, G., Mayer, L., & Plevy, S. E. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07457.x · Cited by 491
The diagnosis and management of anaphylaxis
Lieberman, P., Kemp, S., Oppenheimer, J., Lang, D., Bernstein, I., Nicklas, R., Anderson, J. A., Bernstein, D., Bernstein, J., Fink, J., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 296
Anaphylaxis, killer allergy: Long-term management in the community
Simons, F. E. R. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.002 · Cited by 224
Self-citationMonoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Price, K. S., & Hamilton, R. G. (2007) · Allergy and Asthma Proceedings · doi:10.2500/aap.2007.28.3003 · Cited by 143
Desensitization for drug allergy
Castells, M. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3280108716 · Cited by 122
Steele, R. H., Limaye, S., Cleland, B., Chow, J. S. F., & SURANYI, M. G. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00389.x · Cited by 93
Baudouin, V., Crusiaux, A., Haddad, É., Schandené, L., Goldman, M., Loirat, C., & Abramowicz, D. (2003) · Transplantation · doi:10.1097/01.tp.0000073809.65502.8f · Cited by 83
Cited by
Sorted by citations
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,702
Allergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256
Self-citationThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,185
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 982
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
Busse, W. W., Morgan, W. J., Gergen, P. J., Mitchell, H., Gern, J. E., Liu, A. H., Gruchalla, R. S., Kattan, M., Teach, S. J., Pongracic, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009705 · Cited by 886
The diagnosis and management of anaphylaxis practice parameter: 2010 Update
Lieberman, P. L., Nicklas, R. A., Oppenheimer, J. J., Kemp, S. F., Lang, D. M., Bernstein, D. I., Bernstein, J. A., Burks, A. W., Feldweg, A. M., Fink, J. N., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.06.022 · Cited by 737
Self-citationThe diagnosis and management of acute and chronic urticaria: 2014 update
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D. H., Hsieh, F. H., Sheikh, J. K., Weldon, D., Zuraw, B. L., Bernstein, D. I., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.036 · Cited by 685
Self-citationInternational Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Self-citationAnaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Self-citationFanta, C. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804579 · Cited by 405
Simons, F. E. R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.981 · Cited by 370
Self-citationAnaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, P., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 392
Self-citationSafety and tolerability of omalizumab
Corren, J., Casale, T. B., Lanier, B., Buhl, R., Holgate, S. T., & Jimenez, P. A. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03214.x · Cited by 247
Anaphylaxis: Recent advances in assessment and treatment.
Simons, F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.025 · Cited by 258
Self-citationPractical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
Broyles, A. D., Banerji, A., Barmettler, S., Biggs, C. M., Blumenthal, K. G., Brennan, P. J., Breslow, R. G., Brockow, K., Buchheit, K. M., Cahill, K. N., et al. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.08.006 · Cited by 248
The potential of biologics for the treatment of asthma
Pelaia, G., Vatrella, A., & Maselli, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3792 · Cited by 230
Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.
Campbell, R., Li, J., Nicklas, R., & Sadosty, A. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.10.007 · Cited by 215
Khan, D. A., & Solensky, R. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.028 · Cited by 226
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Kowalski, M. L., Ansotegui, I. J., Aberer, W., Al-Ahmad, M. S., Akdiş, M., Ballmer-Weber, B. K., Beyer, K., Blanca, M., Brown, S. G. A., Bunnag, C., et al. (2016) · World Allergy Organization Journal · doi:10.1186/s40413-016-0122-3 · Cited by 165
Pelaia, C., Calabrese, C., Terracciano, R., Blasio, F. D., Vatrella, A., & Pelaia, G. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618810192 · Cited by 147
Epstein, T. G., Liss, G. M., Murphy-Berendts, K. J., & Bernstein, D. I. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.01.004 · Cited by 138
Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies
Picard, M., & Galvão, V. R. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.12.001 · Cited by 136
Acute infusion reactions induced by monoclonal antibody therapy
Maggi, E., Vultaggio, A., & Matucci, A. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.90 · Cited by 135
Allergic rhinitis: An update on disease, present treatments and future prospects
Mandhane, S. N., Shah, J. H., & Thennati, R. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.07.005 · Cited by 134
Cox, L., Lieberman, P. L., Wallace, D. V., Simons, F. E. R., Finegold, I., Platts‐Mills, T. A. E., & Schwartz, L. B. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.010 · Cited by 131
Self-citationThe use of omalizumab in the treatment of severe allergic asthma: A clinical experience update
Holgate, S. T., Buhl, R., Bousquet, J., Smith, N., Panahloo, Z., & Jimenez, P. A. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.03.008 · Cited by 118
Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatment
Galvão, V. R., & Castells, M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.12.006 · Cited by 118
Nagase, H., Suzukawa, M., Oishi, K., & Matsunaga, K. (2022) · Allergology International · doi:10.1016/j.alit.2022.11.008 · Cited by 117
Hypersensitivity Reactions to Biological Drugs
Gobel, B. H. (2007) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2007.05.009 · Cited by 103
Norman, G., Faria, R., Paton, F., Llewellyn, A., Fox, D., Palmer, S., Clifton, I., Paton, J. Y., Woolacott, N. F., & McKenna, C. (2013) · Health Technology Assessment · doi:10.3310/hta17520 · Cited by 100
Licari, A., Marseglia, A., Caimmi, S. M. E., Castagnoli, R., Foiadelli, T., Barberi, S., & Marseglia, G. L. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0107-z · Cited by 99
Bona, D. D., Fiorino, I., Taurino, M. L., Frisenda, F. M., Minenna, E., Pasculli, C., Kourtis, G., Rucco, A. S., Nico, A., Albanesi, M., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.013 · Cited by 99
Pathophysiology of anaphylaxis
Khan, B. Q., & Kemp, S. F. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283481ab6 · Cited by 90
Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity.
Doña, I., Barrionuevo, E., Blanca‐López, N., Torres, M., Fernández, T. D., Mayorga, C., Canto, G., & Blanca, M. (2014) · PubMed · Cited by 88
Immune modulation for treatment of allergic disease
Nguyen, T. T., & Casale, T. B. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01034.x · Cited by 87
Clinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87
Adverse Reactions to Biologic Therapy
Patel, S. V., & Khan, D. A. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.012 · Cited by 86
Rank, M. A., Chu, D. K., Bognanni, A., Oykhman, P., Bernstein, J. A., Ellis, A. K., Golden, D. B. K., Greenhawt, M., Horner, C. C., Ledford, D. K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.10.026 · Cited by 89
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 83
Monoclonal antibodies for the treatment of refractory asthma
Hambly, N., & Nair, P. K. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000007 · Cited by 83
Omalizumab: Clinical Use for the Management of Asthma
Thomson, N. C., & Chaudhuri, R. (2012) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s7793 · Cited by 81
Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics
Lieberman, P. L., Jones, I., Rajwanshi, R., Rosén, K. E., & Umetsu, D. T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.013 · Cited by 81
Özdemir, C., Akdiş, M., & Akdiş, C. A. (2010) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000315936 · Cited by 77
Recognition and management of severe asthma: A Canadian Thoracic Society position statement
FitzGerald, J. M., Lemière, C., Lougheed, M. D., Ducharme, F. M., Dell, S., Ramsey, C. D., Yang, C. L., Côté, A., Watson, W. T. A., Olivenstein, R., et al. (2017) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2017.1395250 · Cited by 78
Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
Lieberman, P., & Chehade, M. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0316-x · Cited by 74
Overview of the Treatment of Allergic Rhinitis and Nonallergic Rhinopathy
Greiner, A. N., & Meltzer, E. O. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201004-033rn · Cited by 74
Hypersensitivity reactions to biological drugs.
Corominas, M., Gastaminza, G., & Lobera, T. (2014) · PubMed · Cited by 73
Update on optimal use of omalizumab in management of asthma
Pelaia, G. (2011) · Journal of Asthma and Allergy · doi:10.2147/jaa.s14520 · Cited by 70
Bonamichi-Santos, R., & Castells, M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8556-5 · Cited by 74
Immunomodulators for allergic respiratory disorders
Casale, T. B., & Stokes, J. R. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.040 · Cited by 69
Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent
Krings, J. G., McGregor, M. C., Bacharier, L. B., & Castro, M. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.008 · Cited by 71
Chronic spontaneous urticaria in children ‐ a systematic review on interventions and comorbidities
Cornillier, H., Giraudeau, B., Munck, S., Hacard, F., Jonville‐Béra, A. ‐., d'Acremont, G., Pham, B., & Maruani, A. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12870 · Cited by 68
Peanut allergy and anaphylaxis
Finkelman, F. D. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.10.005 · Cited by 66
How to set up a severe asthma service
McDonald, V. M., Vertigan, A. E., & Gibson, P. G. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02012.x · Cited by 64
Giménez‐Arnau, A. M., Toubi, E., Marsland, A. M., & Maurer, M. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13697 · Cited by 60
Kuhl, K., & Hanania, N. A. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32834deebb · Cited by 60
Scott‐Taylor, T. H., Axinia, S., Amin, S., & Pettengell, R. (2017) · Immunity Inflammation and Disease · doi:10.1002/iid3.192 · Cited by 67
Managing Asthma in Primary Care: Putting New Guideline Recommendations Into Context
Wechsler, M. E. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.707 · Cited by 58
Omalizumab: Practical considerations regarding the risk of anaphylaxis
Kim, H. L., Leigh, R., & Becker, A. B. (2010) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-6-32 · Cited by 58
Shaker, M. S., Briggs, A., Dbouk, A., Dutille, E. K., Oppenheimer, J. J., & Greenhawt, M. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.09.037 · Cited by 58
Omalizumab for treatment of allergic rhinitis
Vashisht, P., & Casale, T. B. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.795943 · Cited by 56
Gülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00126-6 · Cited by 56
New perspectives of childhood asthma treatment with biologics
Just, J., Deschildre, A., Lejeune, S., & Amat, F. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.13007 · Cited by 53
A pragmatic guide to choosing biologic therapies in severe asthma
Kavanagh, J. E., Hearn, A. P., & Jackson, D. J. (2021) · Breathe · doi:10.1183/20734735.0144-2021 · Cited by 52
Biological therapies for eosinophilic asthma
Patel, S. S., Casale, T. B., & Cardet, J. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1492540 · Cited by 52
Biologic targeted therapy in allergic asthma
Bice, J. B., Leechawengwongs, E., & Montanaro, A. J. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.12.013 · Cited by 51
Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications
Falduto, G. H., Pfeiffer, A., Luker, A. J., Metcalfe, D. D., & Olivera, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107718 · Cited by 50
Adverse drug reactions to biologics
Scherer, K., Spoerl, D., & Bircher, A. J. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07339.x · Cited by 50
Therapeutic strategies to reduce asthma exacerbations
O’Byrne, P. M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.03.035 · Cited by 49
Risks and safety of biologics: A practical guide for allergists
Sitek, A. N., Li, J. T., & Pongdee, T. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100737 · Cited by 48
Pongdee, T., & Li, J. T. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.11.005 · Cited by 46
Severe Asthma: An Expanding and Mounting Clinical Challenge
Bell, M. C., & Busse, W. W. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.01.005 · Cited by 48
Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients
Domingo, C., Moreno, A., Amengual, M. J., Montón, C., Suarez, D. L., & Pomares, X. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.536208 · Cited by 45
Plötz, S. G., & Ring, J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728211003792518 · Cited by 44
Severe asthma and the omalizumab option
Miller, C. W. T., Krishnaswamy, N., Johnston, C., & Krishnaswamy, G. A. (2008) · Clinical and Molecular Allergy · doi:10.1186/1476-7961-6-4 · Cited by 44
Oliver, E., Chichester, K. L., Devine, K., Sterba, P. M., Wegner, C. D., Vonakis, B. M., & Saini, S. S. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000496162 · Cited by 42
Management of anaphylaxis in primary care: Canadian expert consensus recommendations
Waserman, S., Chad, Z., Francoeur, M., Small, P., Stark, D., Leek, T. V., Kaplan, A. P., & Kastner, M. (2010) · Allergy. European Journal of Allergy and Clinical Immunology · doi:10.1111/j.1398-9995.2010.02418.x · Cited by 46
Harrison, R., MacRae, M., Karsh, J., Santucci, S., & Yang, W. H.-C. (2015) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2015.04.014 · Cited by 41
Cost-Effectiveness of Biologics for Allergic Diseases
Wu, A. C., Fuhlbrigge, A. L., Robayo, M. A., & Shaker, M. S. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.10.009 · Cited by 43
Two decades with omalizumab: what we still have to learn
Incorvaia, C., Mauro, M., Makrì, E., Leo, G., & Ridolo, E. (2018) · Biologics · doi:10.2147/btt.s180846 · Cited by 39
The use of omalizumab in asthma
Price, D. B. (2008) · Primary Care Respiratory Journal · doi:10.3132/pcrj.2008.00031 · Cited by 39
Godse, K. V., Mehta, A. J., Patil, S. P., Gautam, M., & Nadkarni, N. J. (2015) · Indian Journal of Dermatology · doi:10.4103/0019-5154.160490 · Cited by 38
Wang, J., Zou, Z., Xia, H., He, J., Zhong, N., & Tao, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032695 · Cited by 39
A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis
Carter, M. C., Marić, I., Brittain, E., Bai, Y., Lumbard, K., Bolan, H., Cantave, D., Scott, L. M., & Metcalfe, D. D. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.005 · Cited by 38
Gülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal · doi:10.1007/s15007-020-2550-1 · Cited by 36
Omalizumab as monotherapy for food allergy
Arasi, S., Mennini, M., Cafarotti, A., & Fiocchi, A. G. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000744 · Cited by 36
Omalizumab in allergic diseases, a recent review.
Vichyanond, P. (2011) · PubMed · Cited by 34
Omalizumab and hypersensitivity reactions
Shankar, T., & Petrov, A. A. (2012) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32835bf3f5 · Cited by 34
Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17
Landolina, N., & Levi‐Schaffer, F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13396 · Cited by 33
An Update on Biologic-Based Therapy in Asthma
Walsh, G. M. (2013) · Immunotherapy · doi:10.2217/imt.13.118 · Cited by 31
The Use of Omalizumab in Food Oral Immunotherapy
Labrosse, R., Graham, F. J., Roches, A. D., & Bégin, P. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0420-z · Cited by 32
Plosker, G. L., & Keam, S. J. (2008) · BioDrugs · doi:10.2165/00063030-200822030-00005 · Cited by 31
Dugas‐Breit, S., Przybilla, B., Dugas, M., Arnold, A. J., Pfundstein, G., Küchenhoff, H., & Ruëff, F. (2010) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03436.x · Cited by 30
Complexities of Diagnosis and Treatment of Allergic Respiratory Disease in the Elderly
Busse, P. J., & Kilaru, K. (2008) · Drugs & Aging · doi:10.2165/0002512-200926010-00001 · Cited by 30
Redefining Approaches to Asthma
Arron, J. R., Scheerens, H., & Matthews, J. G. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-404717-4.00001-9 · Cited by 29
Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008
Lin, R. Y.-W., Rodriguez-Baez, G., & Bhargave, G. A. (2009) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60366-3 · Cited by 29
Sicherer, S. H., & Leung, D. Y. M. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.01.032 · Cited by 29
Monoclonal Antibodies Hypersensitivity
dos Santos, R. B., & Galvão, V. R. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.07.003 · Cited by 28
Metadata
- Authors
- Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V.
- Affiliations
- Nova Southeastern University (US)
- St. Luke's-Roosevelt Hospital Center (US)
- Virginia Commonwealth University (US)
- University of Manitoba (CA)
- Corresponding author
- Cox, Linda
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 120
- Issue
- 6
- Pages
- 1373-1377
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2010946738
- Cited by
- 295
- References
- 14
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 6 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 26 · 2019: 21 · 2018: 10 · 2017: 15 · 2016: 16 · 2015: 14 · 2014: 18 · 2013: 10 · 2012: 12
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- National Institutes of Health
- Genentech
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- omalizumab, anaphylaxis, anaphylactoid reactions, drug hypersensitivity, post-marketing surveillance, clinical trial safety, patient education, prescribing recommendations
- MeSH terms
- Academies and Institutes, Omalizumab, Allergy and Immunology, Anaphylaxis, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Asthma, Humans, United States, Anti-Allergic Agents, Anti-Asthmatic Agents, Advisory Committees, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
